{"denoms":[{"counts":[{"groupId":"BG000","value":"14"}],"units":"Participants"}],"groups":[{"description":"Zolinza (vorinostat) + CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)\n\nDoxorubicin : 50 mg/m\\^2 by vein over 15 minutes on Day 1 of 21 day cycle\n\nPrednisone : 100 mg tablets by mouth once a day on Days 1-5 of 21 day cycle\n\nZolinza (vorinostat) : Starting oral dose (Schedule A) of 300 mg once a day on Days 5-14 of 21 day cycle.\n\nCyclophosphamide : 750 mg/m\\^2 by vein over 1 hour on Day 1 of 21 day cycle\n\nVincristine : 1.4 mg/m\\^2 by vein over 15 minutes on Day 1 of 21 day cycle","id":"BG000","title":"Zolinza + CHOP"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"29","upperLimit":"83","value":"55"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"300 mg once daily on Days 5 to14"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"200 mg twice daily on Days 5 to14"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"300 mg three times daily on Days -2 to 3"}],"description":"Number of participants who received either Vorinostat treatment Schedule A (300 mg once daily or 200 mg twice daily) for Phase I or Schedule B (300 mg three times daily) for Phase II.","paramType":"NUMBER","title":"Vorinostat Treatment (Schedule A/Schedule B)","unitOfMeasure":"participants"}]}